TrialNet Research Leads to FDA Approval of First Drug to Delay Type 1 Diabetes
Media Release

TrialNet Research Leads to FDA Approval of First Drug to Delay Type 1 Diabetes

Landmark findings from TrialNet research were instrumental in the Food and Drug Administration’s (FDA) November 17, 2022 approval of the first drug to delay type 1 diabetes (T1D) in people at risk.

TrialNet conducted the clinical study that discovered the immunotherapy drug teplizumab could delay T1D for 2+ years.

Read more
Kevan Herold, MD
Media Release

Meet new TrialNet Chair, Dr. Kevan Herold

Kevan C. Herold, MD, C.N.H. Long Professor of Immunology and professor of medicine (endocrinology) at Yale School of Medicine, was recently appointed TrialNet Chair, succeeding Carla J. Greenbaum, MD, who served six years in the position.

Read more
Subscribe to Media Release